Literature DB >> 16714062

Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.

Yoshihisa Shitara1, Yuichi Sugiyama.   

Abstract

3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely used for the treatment of hypercholesterolemia. Their efficacy in preventing cardiovascular events has been shown by a large number of clinical trials. However, myotoxic side effects, sometimes severe, including myopathy or rhabdomyolysis, are associated with the use of statins. In some cases, such toxicity is associated with pharmacokinetic alterations. In this review, the pharmacokinetic aspects and physicochemical properties of statins are reviewed in order to understand the mechanism governing their pharmacokinetic alterations. Among the statins, simvastatin, lovastatin and atorvastatin are metabolized by cytochrome P450 3A4 (CYP3A4) while fluvastatin is metabolized by CYP2C9. Cerivastatin is subjected to 2 metabolic pathways mediated by CYP2C8 and 3A4. Pravastatin, rosuvastatin and pitavastatin undergo little metabolism. Their plasma clearances are governed by the transporters involved in the hepatic uptake and biliary excretion. Also for other statins, which are orally administered as open acid forms (i.e. fluvastatin, cerivastatin and atorvastatin), hepatic uptake transporter(s) play important roles in their clearances. Based on such information, pharmacokinetic alterations of statins can be predicted following coadministration of other drugs or in patients with lowered activities in drug metabolism and/or transport. We also present a quantitative analysis of the effect of some factors on the pharmacokinetics of statins based on a physiologically based pharmacokinetic model. To avoid a pharmacokinetic alteration, we need to have information about the metabolizing enzyme(s) and transporter(s) involved in the pharmacokinetics of statins and, along with such information, model-based prediction is also useful.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16714062     DOI: 10.1016/j.pharmthera.2006.03.003

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  140 in total

1.  Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes.

Authors:  Karelle Ménochet; Kathryn E Kenworthy; J Brian Houston; Aleksandra Galetin
Journal:  Drug Metab Dispos       Date:  2012-06-04       Impact factor: 3.922

2.  Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions.

Authors:  Manthena V S Varma; Yurong Lai; Bo Feng; John Litchfield; Theunis C Goosen; Arthur Bergman
Journal:  Pharm Res       Date:  2012-05-26       Impact factor: 4.200

3.  Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).

Authors:  Manthena V Varma; Stefanus J Steyn; Charlotte Allerton; Ayman F El-Kattan
Journal:  Pharm Res       Date:  2015-07-09       Impact factor: 4.200

Review 4.  Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children.

Authors:  Jonathan Wagner; J Steven Leeder
Journal:  Pediatr Clin North Am       Date:  2012-08-22       Impact factor: 3.278

5.  Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors.

Authors:  Koji Abe; Arlene S Bridges; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2008-12-15       Impact factor: 3.922

6.  Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting.

Authors:  Otito F Iwuchukwu; QiPing Feng; Wei-Qi Wei; Lan Jiang; Min Jiang; Hua Xu; Joshua C Denny; Russell A Wilke; Ronald M Krauss; Dan M Roden; C Michael Stein
Journal:  Pharmacogenomics       Date:  2014-11       Impact factor: 2.533

7.  Atorvastatin attenuation of ABCB1 expression is mediated by microRNA miR-491-3p in Caco-2 cells.

Authors:  Alice C Rodrigues; Elida Adalgisa Neri; Sidney Veríssimo-Filho; Nancy Amaral Rebouças; Rosario D C Hirata; Ai-Ming Yu
Journal:  Eur J Pharm Sci       Date:  2016-08-26       Impact factor: 4.384

8.  Pitavastatin: finding its place in therapy.

Authors:  Leiv Ose
Journal:  Ther Adv Chronic Dis       Date:  2011-03       Impact factor: 5.091

9.  Bama miniature pigs (Sus scrofa domestica) as a model for drug evaluation for humans: comparison of in vitro metabolism and in vivo pharmacokinetics of lovastatin.

Authors:  Yu Liu; Ben-Hua Zeng; Hai-Tao Shang; Yan-Yan Cen; Hong Wei
Journal:  Comp Med       Date:  2008-12       Impact factor: 0.982

10.  Dual drug interactions via P-glycoprotein (P-gp)/ cytochrome P450 (CYP3A4) interplay: recent case study of oral atorvastatin and verapamil.

Authors:  Nuggehally R Srinivas
Journal:  Eur J Clin Pharmacol       Date:  2008-07-26       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.